Technical Analysis for LPCN - Lipocine Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| See historical LPCN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 18 | Slingshot Bullish | Bullish Swing Setup | 0.00% |
| Jan 18 | Wide Bands | Range Expansion | 0.00% |
| Jan 17 | Gilligan's Island Sell Setup | Bearish Swing Setup | -11.17% |
| Jan 17 | New Uptrend | Bullish | -11.17% |
| Jan 17 | Expansion Breakout | Bullish Swing Setup | -11.17% |
| Jan 17 | Pocket Pivot | Bullish Swing Setup | -11.17% |
| Jan 17 | Volume Surge | Other | -11.17% |
| Jan 17 | Wide Range Bar | Range Expansion | -11.17% |
| Jan 17 | New 52 Week High | Strength | -11.17% |
| Jan 17 | Wide Bands | Range Expansion | -11.17% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-14
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Lipocine Inc., a specialty pharmaceutical company, is engaged in the development of pharmaceutical products in the areas of men's and women's health. The company offers a portfolio of proprietary product candidates that are used to produce pharmacokinetic characteristics; facilitate lower dosing requirements and bypass first-pass metabolism; reduce side effects; and eliminate gastrointestinal interactions that limit bioavailability. Its product candidates for men's health include LPCN 1021, an oral product candidate, which is in Phase III clinical trials; and LPCN 1111, an oral product candidate that is in Phase I/II clinical trials for the treatment of testosterone replacement therapy. The company's product candidates for women's health comprise LPCN 1107, which is in Phase I/II clinical trials for the prevention of preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more LPCN news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 2.64 |
| 52 Week Low | 1.03 |
| Average Volume | 629,959 |
| 200-Day Moving Average | 1.4155 |
| 50-Day Moving Average | 1.4456 |
| 20-Day Moving Average | 1.466 |
| 10-Day Moving Average | 1.626 |
| Average True Range | 0.1692 |
| ADX | 28.66 |
| +DI | 52.2852 |
| -DI | 15.8233 |
| Chandelier Exit (Long, 3 ATRs ) | 2.1324 |
| Chandelier Exit (Short, 3 ATRs ) | 1.5476 |
| Upper Bollinger Band | 1.8937 |
| Lower Bollinger Band | 1.0383 |
| Percent B (%b) | 0.74 |
| BandWidth | 58.34925 |
| MACD Line | 0.0878 |
| MACD Signal Line | 0.0592 |
| MACD Histogram | 0.0287 |
| Fundamentals | Value |
|---|---|
| Market Cap | 34.37 Million |
| Num Shares | 20.6 Million |
| EPS | -0.93 |
| Price-to-Earnings (P/E) Ratio | -1.80 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 2.86 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.97 | ||||
| Resistance 3 (R3) | 1.98 | 1.89 | 1.92 | ||
| Resistance 2 (R2) | 1.89 | 1.81 | 1.89 | 1.90 | |
| Resistance 1 (R1) | 1.78 | 1.77 | 1.74 | 1.77 | 1.89 |
| Pivot Point | 1.69 | 1.69 | 1.67 | 1.69 | 1.69 |
| Support 1 (S1) | 1.58 | 1.61 | 1.54 | 1.57 | 1.45 |
| Support 2 (S2) | 1.49 | 1.57 | 1.49 | 1.44 | |
| Support 3 (S3) | 1.38 | 1.49 | 1.42 | ||
| Support 4 (S4) | 1.37 |
